证券之星消息，12月30日重庆国企改革板块较上一交易日下跌0.79%，重药控股领跌。当日上证指数报 收于3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。重庆国企改革板块个股涨跌见下表： 从资金流向上来看，当日重庆国企改革板块主力资金净流出6922.49万元，游资资金净流入434.33万元， 散户资金净流入6488.15万元。重庆国企改革板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Investment Rating - The report assigns a "Strong Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is positioned as a leader in the domestic engineering machinery sector, with a strategic goal to achieve revenue of 60 billion yuan by 2030, focusing on comprehensive solutions, full automation, and internationalization [7][29]. - The company has experienced a significant recovery in the domestic market, with a 21.5% year-on-year growth in excavator sales in the first three quarters of 2025, driven by infrastructure projects and equipment renewal policies [7][9]. - The mixed-ownership reform has revitalized the company's operational vitality, leading to a 52.9% year-on-year increase in net profit for 2024, indicating a shift towards high-quality growth [9][31]. Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 30,063 million, 34,258 million, 39,887 million, and 45,801 million yuan respectively, with year-on-year growth rates of 9.2%, 14.0%, 16.4%, and 14.8% [3]. - Net profit attributable to shareholders is forecasted to be 1,327 million, 1,627 million, 2,237 million, and 2,773 million yuan for the same years, with growth rates of 52.9%, 22.6%, 37.5%, and 24.0% [3]. - Earnings per share (EPS) are expected to be 0.65, 0.80, 1.10, and 1.36 yuan for 2024A, 2025E, 2026E, and 2027E respectively [3]. Business Overview - The company has established a comprehensive product system covering various machinery types, including excavators, loaders, and industrial vehicles, with a global presence in over 180 countries [14][16]. - The company has implemented a "three major growth curves" strategy, focusing on stabilizing its core earth-moving machinery business, accelerating growth in emerging sectors, and enhancing its international presence [7][29]. - The company is transitioning from a product-centric approach to a customer-centric model, providing integrated solutions that encompass the entire lifecycle of equipment [30]. Market Performance - The company has seen a significant increase in overseas revenue, which accounted for 46.9% of total revenue in the first half of 2025, serving as a stabilizing force against domestic market fluctuations [7][34]. - The company’s profitability has improved, with a gross margin stabilizing above 22% and a net margin increasing from 2.44% in 2022 to 4.93% in the first three quarters of 2025 [36]. Strategic Initiatives - The company has launched a convertible bond issuance to fund smart manufacturing and production upgrades, aiming to enhance operational efficiency and risk resilience [27]. - The mixed-ownership reform has led to a diversified shareholding structure, which is expected to facilitate further integration of resources and innovation [19][21]. Future Outlook - The company aims to achieve a revenue target of 60 billion yuan by 2030, with a focus on increasing the international revenue share to over 60% and improving net profit margins [29]. - The strategic emphasis on electric and high-margin products is expected to enhance competitiveness and profitability in the face of domestic price pressures [36].

Core Viewpoint - The company, Zhonghong Medical, is experiencing a decline in stock price and trading volume, while focusing on the development of innovative medical products and benefiting from the depreciation of the RMB [1][4]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, including nitrile and PVC gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, the company reported a revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, but a net profit loss of 7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. Group 2: Market Position and Financials - The company has a significant international presence, with 81.56% of its revenue coming from overseas markets, benefiting from the depreciation of the RMB [4]. - The company operates under an ODM direct sales model, producing medical devices and consumables for overseas brand owners [3]. - As of September 30, 2025, the number of shareholders increased to 22,400, with an average of 17,531 circulating shares per person, a decrease of 10.11% from the previous period [10]. Group 3: Product Development and Innovations - The company is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, which includes a chemical protective layer and a nuclear radiation protective layer [2]. - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2].

证券研究报告·行业深度报告·计算机 计算机行业深度报告 关注地方国企资本运作——国企改革和地方 增收的交汇点 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2025 年 12 月 30 日 证券分析师 王紫敬 执业证书：S0600521080005 021-60199781 wangzj@dwzq.com.cn 行业走势 -14% -10% -6% -2% 2% 6% 10% 14% 18% 22% 26% 2024/12/30 2025/4/30 2025/8/29 2025/12/28 计算机 沪深300 相关研究 《梳理 SpaceX 的 A 股供应商》 2025-12-29 《商业航天 还有哪 些事件 值得期 待？》 2025-12-21 东吴证券研究所 1 / 13 请务必阅读正文之后的免责声明部分 ◼ 土地财政规模承压，盘活存量资产。地方财政收入来源一共"四本账"， 其中国有土地使用权出让收入一直是地方财政收入的重要来源，而 2022 年以来，土地财政收入规模承压，因此 2022 年开始，国家和地方都陆 续出台了各项政策和措施提升土地使用权出让以外的财政收入，路径 ...

Market Overview - The Hang Seng China Central Enterprises Dividend Index increased by 0.52%, the Hang Seng Index rose by 0.50%, and the Hang Seng Technology Index grew by 0.37% last week [1][7] - In the A-share market, the CSI State-Owned Enterprises Dividend Index rose by 0.31%, while the CSI 300 increased by 1.97% [1][7] Central Enterprises Meeting Insights - A meeting of central enterprise leaders was held on December 22-23, emphasizing the need for enhancing core functions, improving competitiveness, and deepening reforms [1][8] - The meeting aimed to prevent and mitigate major risks, promote the growth and optimization of state-owned capital and enterprises, and ensure the successful completion of the "14th Five-Year Plan" [1][8] Operational Indicators of Central Enterprises - The operational indicators of central enterprises are showing overall stability with some optimization, focusing on profit growth and maintaining stable asset-liability ratios [8] - The "one profit and five rates" operational indicator system aims for stable profit growth, stable asset-liability ratios, and improvements in net asset return rate, R&D expenditure intensity, labor productivity, and cash collection rate [8] Profitability and Valuation of State-Owned Enterprises - State-owned enterprises (SOEs) show robust profitability, with a projected annualized ROE for the first three quarters of 2025 significantly higher than the overall A-share market [2][8] - Despite facing long-term valuation challenges, SOEs are expected to have strong dividend willingness and capacity due to improved profit quality and market management [2][8] Dividend Yield and Valuation Metrics - The Hang Seng China Central Enterprises Dividend Index has a dividend yield of 6.97% and a PB ratio of 0.61, with a PE ratio of 6.96, showing a cumulative return of 151% over the past five years [2][8] - The CSI State-Owned Enterprises Dividend Index has a dividend yield of 5.20%, a PB ratio of 0.87, and a PE ratio of 8.71, with a cumulative return of 64% over the same period [2][8] Future Market Outlook - The low interest rate environment and weak economic recovery are favorable for dividend strategies, enhancing the dividend willingness and capacity of central enterprises [2][8] - The Hang Seng China Central Enterprises Dividend ETF (513920) and the State-Owned Enterprises Dividend ETF (561060) are considered to have high allocation value [2][8] ETF Product Overview - The Hang Seng China Central Enterprises Dividend ETF (513920) is the first ETF combining Hong Kong stocks, central enterprises, and dividends, tracking the Hang Seng China Central Enterprises Dividend Index [3][9] - The State-Owned Enterprises Dividend ETF (561060) tracks the CSI State-Owned Enterprises Dividend Index, selecting 100 stocks with high dividend yields and stable dividends from state-owned enterprises [4][11]

Core Viewpoint - The press conference highlighted the achievements of Mianyang's state-owned enterprises (SOEs) during the 14th Five-Year Plan, emphasizing their role in driving high-quality development and contributing to the city's goal of becoming a provincial economic sub-center [2][5]. Group 1: Scale and Performance - The total assets of state-owned enterprises in Mianyang surpassed 1 trillion yuan, reaching 1.4 trillion yuan by November 2025, with revenue of 220.48 billion yuan and industrial output value of 124.06 billion yuan, representing increases of 133.9%, 52.2%, and 49% respectively compared to the end of the 13th Five-Year Plan [2]. - Leading enterprises like Changhong Group ranked 279th in the 2025 World Brand 500 list, improving by 6 positions, while Jiuzhou Group entered the China Enterprise 500 for the first time, contributing to Mianyang having the most state-owned enterprises listed in the province [2]. Group 2: Economic Contribution - The state-owned economy contributed over 40% directly to the city's economy, with the establishment of the "587+" industrial guiding mother fund to foster emerging industries such as artificial intelligence and low-altitude economy [3]. - Infrastructure investments totaled 32.816 billion yuan across 340 projects, including the completion of the South Suburb Airport T2 terminal and the Jiuzhai-Mianyang Expressway [3]. Group 3: Technological Innovation - Mianyang's state-owned enterprises invested over 20 billion yuan in R&D, achieving a research intensity of over 4.5%, maintaining the top position in the province [3]. - Significant technological advancements were made, including the development of international-leading products such as the Changhong quantum gravity meter and Jiuzhou aerospace cables, which filled domestic gaps [3]. Group 4: Reform and Optimization - The city successfully completed the three-year action plan for SOE reform, receiving an "excellent" rating from the provincial state-owned assets supervision and administration commission [4]. - The number of state-controlled listed companies increased to 9, with a focus on optimizing capital layout and integrating similar businesses [4]. Group 5: Social Responsibility - Mianyang's state-owned enterprises employed over 100,000 workers, creating more than 15,000 new jobs during the 14th Five-Year Plan [4]. - Initiatives included rent reductions for 7,769 small and micro enterprises totaling 275 million yuan and investments of over 81 million yuan in targeted assistance for 54 villages [4]. Future Outlook - Moving into the 15th Five-Year Plan, Mianyang aims to further enhance the high-quality development of its SOEs, leveraging technology and industry control to support the city's economic goals [5].

Group 1 - Fu Yuning, born in March 1957, has a strong academic background with a bachelor's degree from Dalian University of Technology and a PhD in Ocean Engineering Mechanics from Brunel University, UK, showcasing both academic depth and international perspective [2] - Under Fu's leadership, China Resources Group's revenue increased from 405.5 billion yuan to 655 billion yuan, and its ranking in the Fortune Global 500 rose by 107 places to 80 by 2019 [2] - Fu Yuning emphasized compliance and value construction through his "Fu Doctor's Observation" column, focusing on corporate culture and business restructuring after the leadership crisis at China Resources Group [2][5] Group 2 - Fu Yuning's core competencies include strategic integration and business restructuring, successfully leading China Merchants Group out of a downturn during the Asian financial crisis by asset divestiture and resource integration [3] - At China Resources Group, he strategically divested low-efficiency businesses and focused on core sectors like beer and pharmaceuticals, leading to the successful listing of China Resources Pharmaceutical in 2016 [3][4] Group 3 - Fu Yuning is adept at integrating industry and finance, having established nine industrial funds at China Resources Group and created an independent capital platform to connect industry and finance [4] - He played a pivotal role in making China Resources Microelectronics a benchmark in the domestic semiconductor industry through acquisitions and listings [4] Group 4 - Fu Yuning's public speeches address key themes such as state-owned enterprise reform and modernization of governance, advocating for market-oriented operational mechanisms [6][7] - He has promoted innovation and transformation strategies, emphasizing the importance of core business integration with technology rather than chasing trends blindly [8] Group 5 - Fu Yuning's international strategy focuses on the challenges of globalization, highlighting the importance of local team building and risk hedging mechanisms in overseas projects [9] - He encourages entrepreneurs to balance commercial success with social responsibility, sharing practices from China Resources in areas like poverty alleviation and environmental protection [10] Group 6 - Even after retiring, Fu Yuning remains active in academia and public service, returning to Dalian University of Technology to inspire students and share insights from his career [11] - As a member of the National Committee of the Chinese People's Political Consultative Conference, he continues to advocate for state-owned enterprise reform and increased R&D investment [12] - Fu Yuning has supported various public welfare projects, including the "China Resources Hope Town" initiative, contributing to rural revitalization [13] Group 7 - Fu Yuning's career reflects the transformation of Chinese state-owned enterprises from administrative to market-oriented structures, demonstrating that "steady operation" and "innovative breakthroughs" are not mutually exclusive [14]

Core Viewpoint - The Chinese rare earth market experienced a decline of 1.19% on December 29, with a transaction volume of 1.169 billion yuan and a total market capitalization of 49.379 billion yuan [1] Company Overview - The company primarily engages in the production and operation of rare earth oxides and provides rare earth technology research and consulting services [2][8] - The company is controlled by the State-owned Assets Supervision and Administration Commission of the State Council, categorizing it as a state-owned enterprise [3][4] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.494 billion yuan, representing a year-on-year growth of 27.73%, and a net profit attributable to shareholders of 192 million yuan, which is a significant increase of 194.67% [8] - The company has distributed a total of 346 million yuan in dividends since its A-share listing, with 124 million yuan distributed over the past three years [9] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 29.0694 million shares, an increase of 9.4669 million shares from the previous period [10] - New entrants among the top shareholders include the Jiashi Zhongzheng Rare Earth Industry ETF and the Southern Zhongzheng Shenwan Nonferrous Metals ETF [10] Market Dynamics - The main capital inflow for the stock today was negative, with a net outflow of 63.4119 million yuan, indicating a lack of clear trend among major investors [5][6] - The average trading cost of the stock is 49.48 yuan, with the current price approaching a resistance level of 47.94 yuan, suggesting potential for a price correction if this level is not surpassed [7]

Group 1 - The market is experiencing a contradiction period where long-term logic clashes with short-term emotions [5] - The Chinese yuan has strengthened, breaking the 7.0 mark, while public fund annual returns have surged to an impressive 236.88%, driven by short-term factors like a weaker dollar and year-end settlement demand [3][4] - Silver prices have skyrocketed to over $83 due to speculative funds and supply imbalances, while some stocks have issued warnings about their prices deviating significantly from fundamentals [4] Group 2 - The State-owned Assets Supervision and Administration Commission (SASAC) is urging state-owned enterprises to resist "involution-style" competition, while the Ministry of Finance has committed to continuing "national subsidies" next year, indicating a focus on quality and efficiency [4] - There is a trend of listed companies engaging in cross-industry acquisitions and targeted fundraising in the automotive sector, reflecting individual corporate anxiety and survival instincts during macroeconomic transitions [4] - Investment opportunities lie in genuine reforms and innovations, while potential traps exist in companies that tell cross-industry stories but have weak core businesses [5][6]

Core Viewpoint - The petrochemical industry faced significant challenges in 2025, with the China Petroleum and Petrochemical Index rising only 15.1%, underperforming compared to the CSI 300 and Wind All A indices, which reflects the impact of fluctuating oil prices and market expectations [4]. Group 1: Oil and Gas Sector Performance - The "Big Three" oil companies (China National Petroleum, Sinopec, and CNOOC) demonstrated resilience amid declining oil prices and narrowing refining margins, achieving stable performance and cash flow in the first three quarters of 2025 [5]. - In the second half of 2025, the negative impact of falling oil prices diminished, leading to a recovery in stock prices for the "Big Three," with respective A-share price changes of +16.3%, -9.8%, and +0.7% [5]. - Looking ahead to 2026, the "Big Three" are expected to maintain high capital expenditures and enhance natural gas market development, aiming for long-term growth despite oil price cycles [5]. Group 2: Refining and Chemical Sector - Leading refining and chemical stocks, such as Hengli Petrochemical and Rongsheng Petrochemical, showed strong price performance, with annual increases of 43.6% and 22.9%, respectively [6]. - The petrochemical industry is currently experiencing low price differentials for key products, indicating potential for recovery as the industry undergoes high-quality development driven by capacity expansion and structural optimization [6]. Group 3: Coal Chemical Sector - Coal chemical companies like Hualu Hengsheng and Baofeng Energy saw stock price increases of 46.2% and 16.9%, respectively, amid a gradual easing of coal supply and demand since 2024 [7]. - As of December 26, 2025, the average prices for domestic coking coal, thermal coal, and anthracite were 1700 RMB/ton, 677 RMB/ton, and 931 RMB/ton, reflecting changes of +11.1%, -11.3%, and -10.5% respectively since the beginning of the year [8]. - The modern coal chemical sector is expected to develop positively in the context of energy transition, with traditional coal enterprises focusing on green transformation and deep clean utilization of coal [8].